
    
      This open label extension protocol enrolls participants who were treated in previous phase 1
      (NCT01149720, NCT01517399, NCT01699061, NCT00612703, NCT00827177, and NCT00874042) and phase
      2 (NCT00777309, NCT00557609, NCT00988741, NCT01395758 , and NCT01055067) tivantinib studies
      that have reached their designated end-dates. Participants enrolled in this extension
      protocol will provide further safety and tolerability information about tivantinib
      monotherapy or in combination with other drug(s) at the same dose(s), and same schedule(s) in
      which they were originally enrolled.
    
  